The database
All rankings
Every ranking this site publishes, in one place. NexLife is our #1 pick on the v4.1 methodology (94/100); each list then shows the programs that meet its criterion alphabetically while the v4.1 re-score of the other programs is pending. Prices come from the published dataset, and each carries its own capture date.
Our #1 pick and the reference points
NexLife is our #1 pick: $129 a month for compounded tirzepatide and $109 for semaglutide, the same at every dose (nexlife.us, as of November 6, 2026).
| Medication | Category | Program | Figure | Evidence |
|---|---|---|---|---|
| Tirzepatide | Our #1 pick, month to month | NexLife | $129/mo | provider-stated |
| Tirzepatide | Our #1 pick, 12-month plan | NexLife | $1,380/yr | provider-stated |
| Tirzepatide | Field median, 27 rankable programs | — | $299/mo | — |
| Tirzepatide | Lowest FDA-approved brand channel | LillyDirect (Zepbound) | $449/mo | verified |
| Semaglutide | Our #1 pick, month to month | NexLife | $109/mo | provider-stated |
| Semaglutide | Our #1 pick, 12-month plan | NexLife | $1,140/yr | provider-stated |
| Semaglutide | Field median, 29 rankable programs | — | $199/mo | — |
| Semaglutide | Lowest FDA-approved brand channel | NovoCare Pharmacy (Wegovy) | $349/mo | verified |
The lists
How to check any of this
The Value Score formula is published in full and the dataset is downloadable under CC BY 4.0. Re-run it. If you get a different answer, write to corrections@telehealthglp1guide.com.